FDA and Patent Office team up to speed drug patent approvals

What it does

This bill creates a formal task force between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) to share information about drug patents and approvals. Patent examiners will gain access to FDA data on drug approvals, labeling changes, and prior art to make better patenting decisions, while the FDA will receive help organizing patent listings. The bill includes confidentiality protections and requires a report in 4 years on how useful the information-sharing has been.

Why we flagged it

The bill's core function is establishing a formal information-sharing task force between two federal agencies to improve patent examination and drug approval consistency. It is procedural and administrative in nature, not a substantive policy change.

What the text implies

• Patent examiners will gain access to non-public FDA communications and product application data, which may accelerate patent grants for drugs by providing earlier visibility into approval timelines and competitive landscape.
• The 30-day notice requirement gives drug sponsors advance warning of information sharing, potentially allowing them to request confidentiality protections or adjust patent strategy before examiners see sensitive data.
• The bill's focus on 'human drugs and biological products' creates a specialized fast-track coordination pathway for pharmaceutical patents that does not extend to other industries, potentially advantaging biotech/pharma patent prosecution.
• Confidentiality protocols are task-force-designed rather than statutorily mandated, leaving room for interpretation and potential scope creep in what information is deemed shareable without explicit congressional oversight.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill improves patent examination accuracy and reduces inconsistencies between agencies, which benefits the public by ensuring patents are granted fairly and drug information is consistent across government. The confidentiality safeguards and 30-day notice requirement protect proprietary information from inappropriate disclosure.

Who stands to gain

• pharmaceutical companies
• biotechnology firms
• patent prosecution service providers

Named in the bill

U.S. Patent and Trademark Office (USPTO), Food and Drug Administration (FDA), Senate Committee on the Judiciary, House Committee on the Judiciary, Under Secretary of Commerce for Intellectual Property, Commissioner of Food and Drugs

Where it stands

4 cosponsors: 2 Democrats, 2 Republicans.

• Mar 24, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 24, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary. (text: CR S1804-1805)”
• Apr 3, 2025 — Reported out of committee · Congress.gov: “Committee on the Judiciary. Ordered to be reported with amendments favorably”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

23 lobbying clients named this bill on 30 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $29,501,310 in lobbying spend. A filing names 20 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 97% of bills with at least one filing.

Richard Durbin, the sponsor, reported $-29,800 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• Biotechnology Innovation Organization — $2,360,000 on 1 filing
• Johnson & Johnson Services Inc — $1,440,000 on 1 filing
• Kaiser Foundation Health Plan Inc — $1,420,000 on 2 filings

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.